Prediction of neutrophil reduction using plasma paclitaxel concentration after administration in patients with uterine, ovarian, or cervical cancers in an outpatient clinic
Improving paclitaxel pharmacokinetics by using tumor-specific mesoporous silica nanoparticles with intraperitoneal delivery
Tags: cancer, chemotherapy, cytoskeletal drug, taxane, Taxol®, terpenoid synthetic pathway
BASi Method Number SAP.1857
Sign up and you’ll receive the latest updates that matter to you, delivered straight to your inbox.
